Skip to main content

Advertisement

Table 3 Subgroup Analyses of the Associations between LMR and progression free survival

From: Prognostic impact of pretreatment lymphocyte-to-monocyte ratio in advanced epithelial cancers: a meta-analysis

Variables No. of studies Test of association Test of heterogeneity
HR 95% CI P value I2 (%) P value
Total 9 0.598 0.465–0.768 < 0.001 89.00 < 0.001
Publication year
 ≤ 2016 4 0.526 0.355–0.777 0.001 83.10 < 0.001
 > 2016 5 0.66 0.470–0.881 0.006 89.60 < 0.001
Initial inclusion period
 ≤ 2006 3 0.502 0.299–0.843 0.009 88.70 < 0.001
 > 2006 6 0.648 0.47–0.882 0.006 89.60 < 0.001
Nationality       
 China 8 0.561 0.466–0.675 < 0.001 64.40 0.006
 Japan 1 1 0.896–1.116 1
Number of cases
 < 200 4 0.684 0.450–1.040 0.075 83.10 < 0.001
 > 200 5 0.551 0.429–0.707 < 0.001 77.60 0.001
Median age (years)
 ≤ 60 5 0.546 0.408–0.729 < 0.001 77.00 0.002
 > 60 4 0.67 0.462–0.971 0.035 87.70 < 0.001
Tumor types
 Cervical carcinoma 1 0.239 0.151–0.379 < 0.001
 Colon cancer and rectal cancer 2 0.695 0.562–0.861 0.001 0.00 0.713
 Ovarian cancer 1 0.581 0.508–0.664 < 0.001
 Esophageal cancer 1 0.461 0.31–0.685 < 0.001
 Lung cancer 4 0.738 0.54–1.007 0.056 80.00 0.002
LMR cutoff
 ≤ 4.0 4 0.609 0.546–0.680 < 0.001 0.00 0.546
 > 4.0 5 0.56 0.351–0.892 0.015 92.20 < 0.001
Therapeutic strategies
 Chemotherapy 4 0.62 0.558–0.688 < 0.001 0.00 0.489
 Molecular targeted 2 0.793 0.472–1.335 0.384 84.10 0.012
 Combined therapy 3 0.415 0.241–0.716 0.002 78.40 0.01
Follow-up period (month)       
 ≤ 33 4 0.619 0.510–0.751 < 0.001 14.20 0.321
 > 33 3 0.457 0.270–0.774 0.004 85.40 0.001
 NR 2 0.826 0.55–1.239 0.356 88.50 0.003
Quality score
 < 7 2 0.826 0.550–1.239 0.356 88.50 0.003
 ≥ 7 7 0.542 0.435–0.674 < 0.001 67.80 0.005
Analysis of hazard ratio
 Multivariate 8 0.592 0.452–0.776 < 0.001 90.40 < 0.001
 Univariate 1 0.644 0.406–1.021 0.061
  1. CI confidence interval, HR hazard ratio, No. number; LMR lymphocyte-to-monocyte ratio